title: The diagnostic role of human epididymis protein 4 and serum amyloid-A in early-stage endometrial cancer patients.
abstract: The aim of this study was to evaluate the prognostic and predictive efficacy of the human epididymis secretory protein 4 (HE4) and serum amyloid-A (S-AA) together with the other tumor markers (CA 125, CA 15-3, CEA, and CA 19-9) in endometrial cancer patients. The study group consisted of 64 patients with defined stage and grade of endometrial cancer and 60 women with benign uterine diseases. Thirty-four healthy women were defined as the control group. Fasting blood samples were collected prior to surgery and tumor marker levels were determined in blood samples by E170 autoanalyzer. S-AA concentrations were measured by particle-enhanced immunonephelometry. Preoperative serum HE4 and S-AA levels were significantly higher in endometrial cancer patients than in controls, whereas the other measured parameters were not significantly different. Serum levels of HE4 were related to both the stage and grade of tumor. The best cutoff point for HE4 was determined to be 59.7 pmol/L; with 75 % sensitivity and 65.5 % specificity. For S-AA, the cutoff point was 8.8 U/mL, with 68.7 % sensitivity and 58.6 % specificity. The combination of HE4, CA 125, CEA, and S-AA raised the sensitivity to 84 %. Preoperative measurement of serum HE4 and S-AA may be of help in early detection of endometrial cancer. Preoperative screening with these markers may provide important information about the patient's outcome and prognosis.
authors: Department of Biochemistry, Istanbul Faculty of Medicine, Istanbul University, 34093, Çapa, Istanbul, Turkey.
authors: Beyhan
authors: B
authors: Omer
authors: Sema
authors: S
authors: Genc
authors: Ozguc
authors: O
authors: Takmaz
authors: Ahmet
authors: A
authors: Dirican
authors: Zeynep
authors: Z
authors: Kusku-Kiraz
authors: Sinan
authors: S
authors: Berkman
authors: Figen
authors: F
authors: Gurdol
mesh_terms: D000230:Adenocarcinoma / Q000378:metabolism* / Q000473:pathology; D000328:Adult; D014408:Biomarkers, Tumor / Q000097:blood*; D018394:CA-125 Antigen / Q000097:blood; D016022:Case-Control Studies; D003937:Diagnosis, Differential; D016889:Endometrial Neoplasms / Q000378:metabolism* / Q000473:pathology; D005260:Female; D006801:Humans; D008565:Membrane Proteins / Q000097:blood; D008875:Middle Aged; D009367:Neoplasm Staging; D011506:Proteins / Q000378:metabolism*; D012372:ROC Curve; D000685:Serum Amyloid A Protein / Q000378:metabolism*; D000081102:WAP Four-Disulfide Core Domain Protein 2
chemical_list: D014408:Biomarkers, Tumor; D018394:CA-125 Antigen; C451759:MUC16 protein, human; D008565:Membrane Proteins; D011506:Proteins; D000685:Serum Amyloid A Protein; D000081102:WAP Four-Disulfide Core Domain Protein 2; C569698:WFDC2 protein, human
references: Reprod Biol Endocrinol. 2003 Jun 18;1:49
references: 12844363
references: Br J Cancer. 2009 Apr 21;100(8):1315-9
references: 19337252
references: Clin Chem Lab Med. 2012 Dec;50(12):2189-98
references: 23096757
references: J Gynecol Oncol. 2009 Sep;20(3):181-6
references: 19809553
references: CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96
references: 18287387
references: Anticancer Res. 1998 May-Jun;18(3B):1897-902
references: 9677441
references: Br J Cancer. 2011 Apr 26;104(9):1418-25
references: 21468050
references: Cancer Res. 2005 Mar 15;65(6):2162-9
references: 15781627
references: Cancer. 2010 Feb 15;116(4):843-51
references: 20041483
references: Environ Health Perspect. 1994 Mar;102(3):306-9
references: 8033872
references: Cancer Res. 2003 Jul 1;63(13):3695-700
references: 12839961
references: Respir Res. 2006 Apr 06;7:61
references: 16600032
references: Clin Cancer Res. 2004 Jun 1;10(11):3919-26
references: 15173101
references: Gynecol Oncol. 2008 Feb;108(2):402-8
references: 18061248
references: J Obstet Gynaecol Can. 2010 Sep;32(9):856-860
references: 21050518
references: Cancer. 2004 Jul 15;101(2):379-84
references: 15241837
references: Obstet Gynecol. 1997 Sep;90(3):441-7
references: 9277659
references: Gynecol Oncol. 2007 Oct;107(1):58-65
references: 17659325
references: Drugs. 2001;61(10):1395-405
references: 11558829
references: Eur J Gynaecol Oncol. 1990;11(4):283-8
references: 2245812
references: Tumour Biol. 2012 Aug;33(4):1141-9
references: 22373583
references: Gynecol Oncol. 1994 Apr;53(1):93-7
references: 8175027
references: Gynecol Oncol. 2012 Aug;126(2):186-91
references: 22525819
references: Clin Radiol. 2007 Jan;62(1):28-34; discussion 35-6
references: 17145260
references: Mod Pathol. 2006 Jun;19(6):847-53
references: 16607372
references: Am J Obstet Gynecol. 2010 Sep;203(3):228.e1-6
references: 20471625
references: Eur J Cancer Clin Oncol. 1988 Jul;24(7):1083-91
references: 2458261
references: Acta Obstet Gynecol Scand. 2006;85(12):1501-5
references: 17260229
references: Expert Rev Mol Diagn. 2009 Sep;9(6):555-66
references: 19732003
references: Cancers (Basel). 2010 Jun 14;2(2):1312-27
references: 24281117
references: Gynecol Oncol. 2002 Jul;86(1):28-33
references: 12079296
references: J Reprod Med. 2005 Aug;50(8):585-90
references: 16220763